Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Inhibition of platelet kinase signaling and scaffolding activities with small molecule proteolysis-targeting chimeras (PROTACs)

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRidim D MoteAMAlexander R. Melrose

Discussion

Loading...

Member takes

Overview

Findings demonstrate that PROTACs reduce phosphorylation and disrupt platelet signaling, suggesting a role in managing kinase-driven conditions.

Key Points

  • This research investigates the impact of proteolysis-targeting chimeras on platelet functions affected by kinase signaling.
  • Biochemical studies on purified human platelets treated with PROTACs targeting BTK and Abl.
  • Western blot analysis to examine protein degradation and phosphorylation changes.
  • Assessment of platelet aggregation and spreading using light transmission aggregometry.
  • BTK degradation with PROTACs reduces phosphorylation of PLCγ2 and disrupts platelet aggregation.
  • Abl degradation shows impaired platelet spreading, suggesting a structural role beyond catalytic function.
  • PROTACs did not alter basal platelet functions, indicating targeted activity in disrupting signaling.

Cite This Study

Mote et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df28https://doi.org/10.1182/blood-2025-3020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PROTACs in platelets: emerging antithrombotic strategies and future perspectives2024 · 5 citations
  2. 2Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis2026
  3. 3Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis2026
  4. 4498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.2024
  5. 5Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy2026